A 4 Week, Double Blind, Placebo Controlled, Randomised, Parallel Group, Multicentre, Phase IIa Study to Investigate the Safety and Tolerability of AZD5069 as Oral Capsules in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2015
At a glance
- Drugs AZD 5069 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Acronyms CIRRUS
- Sponsors AstraZeneca
- 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
- 01 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Feb 2011 Planned End Date changed from 1 Apr 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.